Literature DB >> 21592865

Pre-eclampsia in low and middle income countries.

Tabassum Firoz1, Harshad Sanghvi, Mario Merialdi, Peter von Dadelszen.   

Abstract

Pre-eclampsia and eclampsia are leading causes of maternal and perinatal morbidity and mortality worldwide. The exact prevalence, however, is unknown. The majority of pre-eclampsia related deaths in LMIC occur in the community and therefore, interventions must be focused at this level. There are a number of unique challenges facing LMIC but the principles of care for women with pre-eclampsia remain the same as in well resourced settings. Three primary delays lead to an increased incidence of maternal mortality from pre-eclampsia- delays in triage, transport and treatment. There are a number of other challenges facing LMIC and the health care worker shortage is particularly significant. Task shifting is a potential strategy to address this challenge. Community health care workers, specifically lady health care workers, are an integral part of the health care force in many LMIC and can be employed to provide timely care to women with pre-eclampsia. Prevention strategies should be applied to every pregnant woman since we cannot predict who will develop pre-eclampsia given the limitation in resources. Aspirin and calcium are the only two recommended therapies at this time. Measuring blood pressure and proteinuria is challenging in LMIC due to financial cost and lack of training. A detection tool that is affordable and can be easily applied is needed. Magnesium sulfate is the drug of choice for the prevention and treatment of eclampsia but it is underutilized due to barriers on multiple levels.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21592865     DOI: 10.1016/j.bpobgyn.2011.04.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  49 in total

1.  Promoting Relational Agent for Health Behavior Change in Low and Middle - Income Countries (LMICs): Issues and Approaches.

Authors:  Md Faisal Kabir; Daniel Schulman; Abu S Abdullah
Journal:  J Med Syst       Date:  2019-06-12       Impact factor: 4.460

2.  Should women be advised to use calcium supplements during pregnancy? A decision analysis.

Authors:  Linda J E Meertens; Hubertina C J Scheepers; Jessica P M M Willemse; Marc E A Spaanderman; Luc J M Smits
Journal:  Matern Child Nutr       Date:  2017-06-18       Impact factor: 3.092

3.  High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana.

Authors:  Kathleen M Powis; Thomas F McElrath; Michael D Hughes; Anthony Ogwu; Sajini Souda; Saul A Datwyler; Erik von Widenfelt; Sikhulile Moyo; Marisa Nádas; Joseph Makhema; Esther Machakaire; Shahin Lockman; Max Essex; Roger L Shapiro
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

4.  A retrospective study of HIV, antiretroviral therapy, and pregnancy-associated hypertension among women in Lusaka, Zambia.

Authors:  Marie C D Stoner; Bellington Vwalika; Marcela C Smid; Shalin George; Benjamin H Chi; Elizabeth M Stringer; Jeffrey S A Stringer
Journal:  Int J Gynaecol Obstet       Date:  2016-05-25       Impact factor: 3.561

5.  Photoplethysmography and Heart Rate Variability for the Diagnosis of Preeclampsia.

Authors:  Tammy Y Euliano; Kostas Michalopoulos; Savyasachi Singh; Anthony R Gregg; Mariem Del Rio; Terrie Vasilopoulos; Amber M Johnson; Allison Onkala; Shalom Darmanjian; Neil R Euliano; Monique Ho
Journal:  Anesth Analg       Date:  2018-03       Impact factor: 5.108

Review 6.  Prevention of preeclampsia.

Authors:  Marwan Ma'ayeh; Maged M Costantine
Journal:  Semin Fetal Neonatal Med       Date:  2020-06-02       Impact factor: 3.926

7.  Maternal and fetal outcomes after introduction of magnesium sulphate for treatment of preeclampsia and eclampsia in selected secondary facilities: a low-cost intervention.

Authors:  Jamilu Tukur; Babatunde Ahonsi; Salisu Mohammed Ishaku; Idowu Araoyinbo; Ekechi Okereke; Ayodeji Oginni Babatunde
Journal:  Matern Child Health J       Date:  2013-09

8.  A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.

Authors:  Maged M Costantine; Holly West; Katherine L Wisner; Steve Caritis; Shannon Clark; Raman Venkataramanan; Catherine S Stika; Erik Rytting; Xiaoming Wang; Mahmoud S Ahmed
Journal:  Am J Obstet Gynecol       Date:  2021-05-24       Impact factor: 8.661

9.  Economic and cost-effectiveness analysis of the Community-Level Interventions for Pre-eclampsia (CLIP) trials in India, Pakistan and Mozambique.

Authors:  Jeffrey N Bone; Asif R Khowaja; Marianne Vidler; Beth A Payne; Mrutyunjaya B Bellad; Shivaprasad S Goudar; Ashalata A Mallapur; Khatia Munguambe; Rahat N Qureshi; Charfudin Sacoor; Esperanca Sevene; Geert W J Frederix; Zulfiqar A Bhutta; Craig Mitton; Laura A Magee; Peter von Dadelszen
Journal:  BMJ Glob Health       Date:  2021-05

Review 10.  An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management.

Authors:  Jeffrey Michael Smith; Richard F Lowe; Judith Fullerton; Sheena M Currie; Laura Harris; Erica Felker-Kantor
Journal:  BMC Pregnancy Childbirth       Date:  2013-02-05       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.